Scott Rocklage: Leading Management Specialist, Innovator, And Investor In Biotechnological Ventures

Dr. Scott M. Rocklage joined 5AM Ventures in 2003 as Venture Partner, and one year later, he was promoted to Managing Partner. 5AM Ventures is an investment firm focusing on early-stage life science companies and providing funding for individuals looking to create and develop innovative biotechnological ventures. 5AM Ventures also works with businesses offering later-stage technologies that possess a unique market edge. The investment portfolio of this firm is characterized with corporate spinoffs, drug development, product discovery, medical technologies, as well as products with short growth cycles.


Work and Education History


Dr. Rocklage has studied extensively in the research and development of drugs and other medicines. He studied at MIT and the University of California, Berkeley, receiving Ph.D. and B.S degree in Chemistry respectively. While at MIT, he was privileged to conduct his thesis research in the laboratory of Richard R. Schrock, a recipient of the 2005 Nobel Prize in Chemistry.


Scott Rocklage bears more than 30 years of management expertise and leadership in the strategic planning and administration of healthcare. He currently operates on the boards of Pulmatrix, EPIRUS Biopharmaceuticals, WaveRx, Massachusetts Biotechnology, Cidara, and Achaogen. Dr. Rocklage has previously served as a member of the boards of Relypsa, Ilypsa, and Novira. He serves on the Whitehead Institute’s Board of Associates.


He also held several positions in both R&D and the top management of biotechnological firms such as Nycomed International, Nycomed Salatur, and Cubist Pharmaceuticals. As the CEO and Chairman of Cubist Pharmaceuticals, he facilitated profitable rounds of financing and a highly successful initial public offering, amounting to a total of $500 million. Scott Rocklage was involved in the development of three new FDA-approved drugs, and several clinical trials.


He is listed on more than 30 medical technology patents in the U.S, as either inventor or co-creator. Scott Rocklage has also published over 100 peer-reviewed studies and research papers.


Philanthropic Activities and Contributions


In 2016, he committed himself to financially assisting with the renovation and maintenance of several buildings in MIT’s Chemistry Department. These include the nanotechnology and nanochemistry lab space dedicated to Moungi Bawendi, a Lester Wolfe Professor of Chemistry.


Scott Rocklage also supports nonprofits such as the Sudbury Valley Trustees and the U.S Lacrosse Foundation.